A Better & Stable Cold High-Level Disinfectant Formulation for Medical Equipments
一个更好的
基本信息
- 批准号:7596033
- 负责人:
- 金额:$ 14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-01-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAerobicAffectAldehydesAlkylating AgentsAnti-Bacterial AgentsAreaBiocideBiopsyBoratesBuffersCause of DeathCenters for Disease Control and Prevention (U.S.)Cessation of lifeChemicalsChlorineClinical EngineeringCosmeticsCross InfectionDataDental EquipmentDepartment of DefenseDiagnosticDialysis procedureDisastersDiseaseDisease OutbreaksDisinfectantsDisinfectionDrug FormulationsEndoscopesEndoscopyEnsureEquipmentExerciseExhibitsExposure toFormaldehydeGlutaralGoalsGovernmentHIVHandHealthHealth ProfessionalHealth care facilityHealthcareHeatingHepatitis BHospitalsHumanHuman ResourcesHydrogen PeroxideIndustryInfectionJournalsLifeLiquid substanceMalignant NeoplasmsMarketingMedicalMicrobeMycobacterium tuberculosisNeedle biopsy procedureNosocomial InfectionsNotificationOperative Surgical ProceduresOrganismOxidantsPatientsPeracetic AcidPeroxidesPhaseProceduresProcessPropertyReactive Oxygen SpeciesRelative (related person)ReportingReproduction sporesResearchResearch ProposalsRiskRisk FactorsSafetySeveritiesSodiumSolidSolutionsSourceSteamSterilitySterilization for infection controlStressStructureTechnologyTemperatureTestingTimeTransportationVisitVital StatisticsWarWaterWeightWorkadductaqueousbasebiomaterial compatibilitybisulfitecostcost effectivenesseconomic costflexibilityhazardinstrumentkillingsnovelo-Phthalaldehydepathogenpreventpublic health relevancesolid statevapor
项目摘要
DESCRIPTION (provided by applicant): We are developing a novel two-part cold high-level disinfecting/sterilization technology that will be ready to work by mixing in water, just minutes before use. Both components separately are inactive stable derivatives of active high level disinfectant agents, have good shelf life, and easy handling restriction compared to dialdehydes, ensuring the cost-effectiveness. After mixing the two components in water just before use, the mixture would generate a mixture of active ingredients of two separate disinfectant agents for a wider scope of bioactivity. This will (1) limit personnel exposure to aldehyde vapors to a minimum, (2) be effective with short contact times at mild solution temperatures, (3) exhibit a wider spectrum of disinfection capabilities, (4) have no storage and transportation hazards and be quite stable on long term storage, (5) be suitable even for austere conditions, like in war and other disaster areas where normal sterilization conditions are not available, except the use of potable water. Our research will include the synthesis, purification, characterization, and packaging of the two parts of inactive formulation, which will be added to water to form an active disinfectant solution just before testing on FDA required sporicidal test on B. subtilis and C. sporogenes, and the AOAC Quantitative TB Test. The above experimental formulations will also be tested for handling the bioburden stress compared to that handled by control commercial disinfectant solutions. The long term objective is to commercialize this product, after an advanced research in the phase-II leading to acquiring the necessary data related to high- level disinfectant and sterilization and submission of pre-market notification [510(k)], which will include optimization of formulation for the best disinfectant, shelf life stability, instrument and human safety, and biocompatibility properties. PUBLIC HEALTH RELEVANCE: There have been many reports of outbreaks of nosocomial infections from diagnostic, medical, surgical and dental equipments, including the recent ones from nation's most prestigious hospitals. Unfortunately, no ideal high-level disinfectants (HLDs) exist, as all products in market have limitations. Potential inactivity of dialdehydes against certain important microbes and some spores is well established now. The only high-level disinfectants to kill such microbes are peroxides. Also, liquid dialdehydes have the problem of exposure of personnel, including their special needs in transportation and storage. Therefore, an effort is required to develop a HLD / sterilant, which could be stored and transported as inactive solid derivative of the disinfectant to eliminate the risk of exposure, reduce the storage / transportation costs and enhance the stability; the product could be formulated just before use by solubilizing this component with another solid stable disinfectant in water that would allow release of the two disinfectant components in appropriate amounts for a more wide spectrum bioactivity. It is expected that both components separately have good shelf life, and easy handling restriction compared to current dialdehydes. The product will (1) limit personnel exposure to aldehyde vapors to a minimum, (2) be effective with short contact times at mild solution temperatures, (3) exhibit a wider spectrum of disinfection capabilities, (4) have no storage and transportation hazards and be quite stable on long term storage, (5) be suitable even for austere conditions, like in war and other disaster areas where normal sterilization conditions are not available, except the use of potable water.
描述(由申请人提供):我们正在开发一种新型的两部分冷高级消毒/灭菌技术,只需在使用前几分钟将其与水混合即可。两种成分分别为活性高级消毒剂的非活性稳定衍生物,与二醛相比,具有良好的保质期,易于处理限制,确保了成本效益。在使用前将两种成分在水中混合后,会产生两种不同消毒剂的有效成分的混合物,具有更广泛的生物活性。这将(1)将人员接触乙醛蒸气的时间限制在最低限度,(2)在温和的溶液温度下,在短时间内有效,(3)表现出更广泛的消毒能力,(4)没有储存和运输危险,并且在长期储存中相当稳定,(5)甚至适用于恶劣条件,如战争和其他灾区,除了使用饮用水之外,没有正常的灭菌条件。我们的研究将包括两部分非活性制剂的合成、纯化、表征和包装,在FDA要求的枯草芽孢杆菌和芽孢杆菌的杀孢试验和AOAC定量结核病试验之前,将其加入水中形成活性消毒剂溶液。还将对上述实验配方进行处理生物负荷压力的测试,并与对照商业消毒剂溶液进行比较。长期目标是将该产品商业化,在ii期的高级研究之后,获得与高级消毒剂和灭菌相关的必要数据,并提交上市前通知[510(k)],其中包括最佳消毒剂配方的优化,保质期稳定性,仪器和人体安全性以及生物相容性。公共卫生相关性:有许多关于诊断、医疗、外科和牙科设备爆发医院感染的报告,包括最近来自国家最负盛名的医院的感染。不幸的是,没有理想的高级消毒剂(hld)存在,因为市场上所有的产品都有局限性。二醛对某些重要微生物和一些孢子的潜在无活性现已得到充分证实。唯一能杀死这类微生物的高级消毒剂是过氧化物。此外,液体二醛存在人员接触的问题,包括在运输和储存方面的特殊需要。因此,需要努力开发一种HLD /消毒剂,它可以作为消毒剂的非活性固体衍生物储存和运输,以消除接触风险,降低储存/运输成本,提高稳定性;该产品可以在使用前通过将该成分与另一种固体稳定消毒剂在水中溶解来配制,这将允许释放适量的两种消毒剂成分,以获得更广泛的生物活性。与目前的二醛相比,这两种成分分别具有良好的保质期和易于处理的限制。该产品将(1)将人员接触乙醛蒸气的时间限制在最低限度,(2)在温和的溶液温度下,在短时间内有效,(3)表现出更广泛的消毒能力,(4)没有储存和运输危险,并且在长期储存中相当稳定,(5)甚至适用于恶劣条件,如战争和其他灾区,这些地区没有正常的灭菌条件,除了使用饮用水。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rajiv Kumar Satsangi其他文献
Rajiv Kumar Satsangi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rajiv Kumar Satsangi', 18)}}的其他基金
A Dual-drug Delivery to Inhibit Causes of Periodontal Diseases
抑制牙周病病因的双药递送
- 批准号:
8311852 - 财政年份:2012
- 资助金额:
$ 14万 - 项目类别:
A Novel Biomimetic Calcium Phosphate Coating for Metallic Orthopedic Implants
用于金属骨科植入物的新型仿生磷酸钙涂层
- 批准号:
7161027 - 财政年份:2006
- 资助金额:
$ 14万 - 项目类别:
A New High-Level Disinfectant for Medical Instruments
新型医疗器械高级消毒剂
- 批准号:
7117443 - 财政年份:2005
- 资助金额:
$ 14万 - 项目类别:
A New High-Level Disinfectant for Medical Instruments
新型医疗器械高级消毒剂
- 批准号:
6883073 - 财政年份:2005
- 资助金额:
$ 14万 - 项目类别:
BMP-2 Releasing Implant Surface for Bone Regeneration
BMP-2 释放植入物表面以促进骨再生
- 批准号:
6582613 - 财政年份:2003
- 资助金额:
$ 14万 - 项目类别:
A Novel Surface Modification Method for Dental Implants
一种新型的牙种植体表面修饰方法
- 批准号:
6403358 - 财政年份:2001
- 资助金额:
$ 14万 - 项目类别:
相似海外基金
Developing Late Metal Catalytic Systems for Aerobic Partial Oxidation of Alkanes
开发烷烃有氧部分氧化的后金属催化系统
- 批准号:
2247667 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Standard Grant
Targeting aerobic glycolysis via hexokinase 2 inhibition in Natural Killer T cell lymphomas
通过抑制己糖激酶 2 靶向自然杀伤 T 细胞淋巴瘤中的有氧糖酵解
- 批准号:
23K07830 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Precision Medicine in Alzheimer’s Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses
阿尔茨海默病的精准医学:使用 AT(N) 生物标志物优化有氧健身反应的适应性运动及其作用机制的 SMART 试验
- 批准号:
10581973 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
MIND Foods and Aerobic Training in Black Adults with HTN: An ADRD Prevention Pilot RCT (MAT)
MIND 食品和患有 HTN 的黑人成人的有氧训练:ADRD 预防试点随机对照试验 (MAT)
- 批准号:
10585366 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults
同时进行有氧运动和认知训练可预防高危老年人的阿尔茨海默病
- 批准号:
10696409 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Investigating the physical and chemical controls on aerobic methane oxidation
研究好氧甲烷氧化的物理和化学控制
- 批准号:
2241873 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Standard Grant
Effect of aerobic exercise-induced sleep changes on arterial stiffness associated with postprandial hyperglycemia.
有氧运动引起的睡眠变化对与餐后高血糖相关的动脉僵硬度的影响。
- 批准号:
23K10645 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pro-Resolving Inflammatory Mediators in Neurovascular Gains in Aerobic Training; a phase 2, double-blind, randomized placebo-controlled trial (PRIMiNG-AT2)
有氧训练中促进神经血管增益的炎症介质的消除;
- 批准号:
485524 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
Operating Grants
Regulators of Photoreceptor Aerobic Glycolysis in Retinal Health and Disease
视网膜健康和疾病中光感受器有氧糖酵解的调节因子
- 批准号:
10717825 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别:
The Effects of Aerobic Exercise on Cardiovascular Health in Postmenopausal Females: A Systematic Review and Meta-Analysis
有氧运动对绝经后女性心血管健康的影响:系统评价和荟萃分析
- 批准号:
480729 - 财政年份:2023
- 资助金额:
$ 14万 - 项目类别: